Ipamorelin vs Semaglutide
Well Studied vs FDA Approved
monitor Mechanism-based · 47% Both Ipamorelin and Semaglutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
Ipamorelin Semaglutide
Weight 711.85 Da 4,113.64 Da
Half-life ~2 hours ~7 days (168 hours)
Chain 5 amino acids 31 amino acids
Type Growth hormone secretagogue GLP-1 receptor agonist
Key Benefits
Ipamorelin
01 Optimal GH stimulation with superior bioavailability
02 Body composition improvements (lean mass, fat loss)
03 Enhanced recovery and anti-aging effects
04 Minimal side effects compared to other GHRPs
05 No significant cortisol or prolactin elevation
06 Improved sleep quality
Semaglutide
01 15-20% average body weight reduction
02 Established cardiovascular protection
03 Convenient once-weekly dosing options
04 Comprehensive safety data from extensive trials
05 Flexible injectable and oral formulations
Dosing Protocols
Ipamorelin
200-300 mcg per injection / 1-3 times daily depending on goals (1x for longevity, 2-3x for performance)
General Health & Longevity 200mcg 1x daily before bed
Body Composition 250-300mcg 2x daily (morning, pre-workout)
Athletic Performance 200-250mcg 2-3x daily
Sleep & Recovery 200mcg 1x daily 30min before bed
Anti-Aging Protocol 200-250mcg 1-2x daily
Semaglutide
0.25mg starting, titrate to 1-2.4mg weekly / Once weekly (same day each week)
Weight Loss Initiation 0.25mg Weekly x 4 weeks, then increase
Weight Loss Maintenance 2.4mg Weekly (after 16-week titration)
Diabetes Management 0.5-1mg Weekly
Cardiovascular Protection 0.5-1mg Weekly
Tolerability-Based 0.25-2.4mg Weekly (individualized)
Side Effects
Ipamorelin
Mild hunger increase 20-30 minutes post-injection
Slight drowsiness when taken before bed
Water retention (mild)
Semaglutide
Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
Contraindications
Pregnancy or breastfeeding
Active cancer or history of cancer
Severe kidney or liver disease
Personal or family history of medullary thyroid cancer
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnancy or breastfeeding
History of pancreatitis
Research Evidence
Ipamorelin Semaglutide
Status Well Studied FDA Approved
References 5 studies 9 studies
Latest October 2024 2025-06
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.